Abstracts Archive - Page 1378 of 2607 - ACR Meeting Abstracts

Abstract Number: 2877 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Gregory St. John², Carol J. Etzel¹, Stefano Fiore³, Taylor Blachley¹, Toshio Kimura², Rajeshwari Punekar³, Kelechi Emeanuru⁴, Susan Boklage² and Joel Kremer^1,5, ¹Corrona LLC, Waltham, MA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi, Bridgewater, NJ, ⁴Corrona, LLC, Waltham, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: RA patients who are intolerant or have an inadequate response to conventional synthetic DMARDs (csDMARDs) can be treated with a biologic DMARD (bDMARD). Tumor…
Abstract Number: 2878 • 2018 ACR/ARHP Annual Meeting
Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Andreas Kerschbaumer¹, Harald Herkner², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department for Emergency Medicine, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Phase 3 (P3) clinical trials are the mainstay of drug development in all areas of medicine, including rheumatology, allowing to determine safety and efficacy…
Abstract Number: 2879 • 2018 ACR/ARHP Annual Meeting
Plasma IL-23 and IL-25 Predict Response to Anti-TNF-α Therapy in Rheumatoid Arthritis
Niamh Fanning¹, Melanie J Millier², John Highton², Christopher Frampton³, Paul A Hessian² and Lisa K. Stamp³, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Department of Medicine, University of Otago, Dunedin, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: TNF-α inhibitors are among the most widely used biological-DMARDs in rheumatoid arthritis (RA). Means to predict response would allow for a more effective, targeted…
Abstract Number: 2880 • 2018 ACR/ARHP Annual Meeting
Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation
Saviana Gandolfo¹, Cinzia Fabro¹, Michela Bulfoni², Elena Doriguzzi Breatta¹, Daniela Cesselli², Carla Di Loreto² and Salvatore De Vita¹, ¹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ²Institute of Anatomic Pathology, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy
Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been demonstrated to be involved in B-cell lymphoproliferation and lymphoma mainly by tissue studies on salivary glands (SG) biopsies…
Abstract Number: 2881 • 2018 ACR/ARHP Annual Meeting
How Immunological Profile Drives Clinical Phenotype of Primary Sjögren’s Syndrome at Diagnosis: Analysis of 10.500 Patients (Sjögren Big Data Project)
Soledad Retamozo^1,2, Nihan Acar-Denizli³, Wan-Fai Ng⁴, Margit Zeher⁵, Astrid Rasmussen⁶, Thomas Mandl⁷, Raphaele Seror⁸, Xiaomei Li⁹, Chiara Baldini¹⁰, Jacques-Eric Gottenberg¹¹, Debashish Danda¹², Luca Quartuccio¹³, Roberta Priori¹⁴, Gabriela Hernandez-Molina¹⁵, Berkan Armagan¹⁶, Aike A. Kruize¹⁷, Seung-Ki Kwok¹⁸, Marika Kvarnström¹⁹, Sonja Praprotnik²⁰, Damien Sène²¹, Elena Bartoloni²², Roser Solans²³, Maureen Rischmueller²⁴, Yasunori Suzuki²⁵, David A. Isenberg²⁶, Valeria Valim²⁷, Piotr Wiland²⁸, Gunnel Nordmark²⁹, Guadalupe Fraile³⁰, Hendrika Bootsma³¹, Takashi Nakamura³², Roberto Giacomelli³³, Valérie Devauchelle-Pensec³⁴, Andreas Knopf³⁵, Michele Bombardieri³⁶, Virginia Fernandes Trevisani³⁷, Daniel S. Hammenfors³⁸, Sandra G Pasoto³⁹, Tamer A. Gheita⁴⁰, Fabiola Atzeni⁴¹, Jacques Morel⁴², Cristina Vollenveider⁴³, Ildiko-Fanny Horvath⁵, Kathy L. Sivils⁴⁴, Peter Olsson⁴⁵, Salvatore De Vita⁴⁶, Jorge Sánchez-Guerrero⁴⁷, Levent Kilic¹⁶, Marie Wahren-Herlenius⁴⁸, Xavier Mariette⁸, Manuel Ramos-Casals⁴⁹ and Pilar Brito-Zerón^50,51, ¹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ²Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ³Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Istanbul, Turkey, Istanbul, Turkey, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, Newcastle, United Kingdom, ⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ⁷Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, Lund, Sweden, ⁸Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France, ⁹Department of Rheumatology and Immunology, Anhui Provincial Hospital, Hefei., Hefei, China, ¹⁰Rheumatology Unit, University of Pisa, Pisa, Italy, ¹¹Rhumatologie, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ¹²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹³Clinic of Rheumatology, Department of Medical Area (DAME), University Hospital “Santa Maria della Misericordia”, Udine., Udine, Italy, ¹⁴Department of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome., Rome, Italy, ¹⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ¹⁶Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁷Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁸Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul., Seoul, Korea, Republic of (South), ¹⁹Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²⁰Department of Rheumatology, University Medical Centre, Ljubljana., Ljubljana, Slovenia, ²¹Lariboisière Hospital, Paris Diderot University, Paris, France, ²²Rheumatology Unit, University of Perugia, Perugia, Italy, ²³Department of Internal Medicine, Hospital Vall d’Hebron, Barcelona, Barcelona, Spain, ²⁴The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia, ²⁵Ishikawa, Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Ishikawa, Ishikawa, Japan, ²⁶Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ²⁷Department of Medicine, Federal University of Espírito Santo and University Hospital HUCAM/EBSERH, Vitória, Vitoria, Brazil, ²⁸Department of Rheumatology and Internal Medicine, Wroclaw Medical Hospital, Wroclaw, Wroclaw, Poland, ²⁹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ³⁰Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Madrid, Spain, ³¹Department of Rheumatology & Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ³²Department of Radiology and Cancer Biology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³³Clinical Unit of Rheumatology, University of l’Aquila, School of Medicine, L’Aquila, L’Aquila, Italy, ³⁴Rheumatology Department, Brest University Hospital, Brest, Brest, France, ³⁵Otorhinolaryngology/ Head and Neck Surgery, Klinikum rechts der Isar, Technical University Munich, Munich, Germany, ³⁶Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ³⁷Federal University of São Paulo, São Paulo, Brazil, ³⁸Department of Rheumatology, Haukeland University Hospital, University of Bergen, Bergen, Norway, ³⁹Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁴⁰Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt, ⁴¹IRCCS Galeazzi Orthopaedic Institute, Milan, and Rheumatology Unit, University of Messina, Messina, Italy, ⁴²Department of Rheumatology, Montpellier University Hospital and University of Montpellier, Montpellier, France, ⁴³German Hospital, Buenos Aires, Buenos Aires, Argentina, ⁴⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma, OK, ⁴⁵Department of Rheumatology, Skane University Hospital Malmö, Lund University, Malmö, Malmö, Sweden, ⁴⁶Clinic of Rheumatology, Department of Medical Area (DAME), University Hospital “Santa Maria della Misericordia”, Udine, Udine, Italy, ⁴⁷Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico, Mexico, ⁴⁸Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁴⁹University of Barcelona, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵⁰Sjögren’s Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic, Barcelona, Bercelona, Spain, ⁵¹Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA Sanitas, Barcelona, Barcelona, Spain
Background/Purpose: To evaluate the influence of the main immunological markers on the disease phenotype at diagnosis in a large international cohort of patients with primary…
Abstract Number: 2882 • 2018 ACR/ARHP Annual Meeting
Minimal Progression of Disease Manifestation in Patients with Sjögren’s Syndrome Re-Evaluated Multiple Years after Initial Disease Classification
Astrid Rasmussen¹, Lida Radfar², Kimberly Hefner³, David M. Lewis⁴, C. Erick Kaufman⁵, Donald U. Stone⁶, Kerry M. Leehan¹, Kiely Grundahl⁷, Christopher J. Lessard¹, A. Darise Farris⁸, R. Hal Scofield⁹ and Kathy L. Sivils¹⁰, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ³Hefner Eye Care Center, Oklahoma City, OK, ⁴Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁵Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, ⁶Ophthalmology, Johns Hopkins University, Baltimore, MD, ⁷Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Classical connective tissue diseases, such as SLE and RA have well documented progression of disease and damage accrual. However, the natural history of Sjögren’s…
Abstract Number: 2883 • 2018 ACR/ARHP Annual Meeting
Testing for Anti-Microbial Antibodies with Cross-Reactivity to Human Tissue in Autoimmune Diseases
Peilin Zhang, Lawrence Minardi, J. Todd Kuenstner and Stephen Zekan, PZM Diagnostics, LLC, Charleston, WV
Background/Purpose: Autoantibodies are defining features of autoimmune diseases. How and why the autoantibodies are produced and how these autoantibodies relate to pathogenesis is poorly understood.…
Abstract Number: 2884 • 2018 ACR/ARHP Annual Meeting
Correlation between Salivary Gland Ultrasonography, Minor Salivary Gland Histhopatology and Sialometry: Towards a Composite Assessment of Salivary Gland Involvement in Primary Sjögren’s Syndrome
Chiara Baldini¹, Nicoletta Luciano¹, Francesco Ferro¹, Antonella Cecchettini², Valentina Donati³, Marta Mosca¹ and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²IFC, CNR, Pisa, Italy, ³Pathology Unit, University of Pisa, Pisa, Italy
Background/Purpose:: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease that specifically involves salivary glands. Several complementary tools including salivary gland ultrasonography (SGUS), histology and…
Abstract Number: 2885 • 2018 ACR/ARHP Annual Meeting
Expansion of Activated PD-1+ ICOS+ T Follicular and Peripheral Helper Cells in Primary Sjögren’s Syndrome Associates with Abnormalities in B Cell Compartment
Nida Meednu¹, Jennifer Albrecht², Madhu Ramaswamy³, Jeffrey Riggs⁴, Alex Rosenberg⁵, Jamie Biear⁶, Ralf G. Thiele⁷, Andreea Coca², Gianluca Carlesso³ and Jennifer Anolik², ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³MedImmune LLC, Gaithersburg, MD, ⁴Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁷Division of Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by immune cell infiltration in the salivary glands resulting in ocular and oral dryness.…
Abstract Number: 2886 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies
Laura C. Coates¹, Dennis McGonagle², Georg Schett³, Philip J. Mease⁴, Erhard Quebe-Fehling⁵, D. L. Asquith⁶, L. Rasouliyan⁷, Shephard Mpofu⁵ and Corine Gaillez⁵, ¹University of Oxford, Oxford, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Swedish Medical Centre and University of Washington, Seattle, WA, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals UK Ltd, Camberley, United Kingdom, ⁷RTI Health Solutions, Barcelona, Spain
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively neutralizes IL-17A, provided significant and sustained improvement in the signs and symptoms of active PsA,…
Abstract Number: 2887 • 2018 ACR/ARHP Annual Meeting
Chronic Pain and Assessment of Pain Sensitivity in Patients with Established Axial Spondyloarthritis – a Cross-Sectional Study
Elisabeth Mogard¹, Tor Olofsson², Stefan Bergman³, Ann Bremander⁴, Lars Erik Kristensen⁵, Jack Kvistgaard Olsen⁶, Johan K Wallman⁷ and Elisabet Lindqvist⁸, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Faculty of Medicine and Skåne University Hospital, Lund, Sweden, ²Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ³University of Gothenburg, Gothenburg, Sweden, ⁴Spenshult Research and Development Center, Halmstad, Sweden, ⁵Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁶Department of Rheumatology, Copenhagen University Hospital, Fredriksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁷Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ⁸Department of Clinical Sciences Lund,Section of Rheumatology, Lund University, Faculty of Medicine and Skåne University Hospital, Lund, Sweden
Background/Purpose: Pain remains a common and debilitating symptom in arthritis, despite good options to treat inflammation. In axial spondyloarthritis (axSpA), data on chronic pain remain…
Abstract Number: 2888 • 2018 ACR/ARHP Annual Meeting
Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis
Borja Hernández-Breijo¹, Victoria Navarro-Compán¹, Ana Martínez¹, Andrea Jochems¹, Alejandro Villalba², Diana Peiteado³, Eva L. Kneepkens⁴, Gerrit Wolbink⁴, Theo Rispens⁵, Dora Pascual-Salcedo¹, Alejandro Balsa¹ and Chamaida Plasencia¹, ¹Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Reade, Amsterdam, Netherlands, ⁵Immunopathology, Sanquin Research, Amsterdam, Netherlands
Background/Purpose: In patients with axial spondyloarthritis (axSpA), the use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate (MTX) and sulfasalazine (SSZ), as well…
Abstract Number: 2889 • 2018 ACR/ARHP Annual Meeting
Inhibition of Radiographic Progression and Correlation with Changes in Composite Indices of Disease Activity in Patients with Active Psoriatic Arthritis Treated with Intravenous Golimumab, As Measured in a Phase III Trial
Philip J. Mease¹, Shelly Kafka², Soumya D Chakravarty³, Diane D. Harrison⁴, Kim Hung Lo⁴, Stephen Xu⁴, Elizabeth C Hsia⁵ and Arthur Kavanaugh⁶, ¹Swedish Medical Centre and University of Washington, Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, ⁶University of California, San Diego, School of Medicine, La Jolla, CA
Background/Purpose: GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM), an anti-tumor necrosis factor alpha (TNFα) monoclonal antibody, in adult patients (pts) w/…
Abstract Number: 2890 • 2018 ACR/ARHP Annual Meeting
Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study
Jun Won Park¹, Min Jung Kim¹, Hyoun-Ah Kim², Kichul Shin³, Yong-Beom Park⁴, Yeong Wook Song⁵ and Eun Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ⁴Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Although recent treatment guideline of axial spondyloarthritis (axSpA) by the European League Against Rheumatism (EULAR) recommended that tapering of tumor necrosis factor inhibitor (TNFi)…
Abstract Number: 2891 • 2018 ACR/ARHP Annual Meeting
Eligibility Criteria for TNFi Therapy in Axial Spa: Going Beyond Basdai
José Marona^1,2, Alexandre Sepriano^2,3, Santiago Rodrigues Manica^1,2, Fernando Pimentel-Santos^1,2, Ana Filipa Mourão^1,2, Nélia Gouveia², Jaime Cunha Branco^1,2, Filipe Vinagre⁴, Raquel Roque⁴, João Rovisco⁵, Mary Lucy Marques⁵, José Tavares Costa⁶, Joana Leite Silva⁶, Helena Santos⁷, Nathalie Madeira⁷, Elsa Vieira-Sousa^8,9, Ana Rita Machado¹⁰, Miguel Bernardes¹¹, Raquel Ferreira¹¹ and Sofia Ramiro^2,12,13, ¹Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ²CEDOC, NOVA Medical School, Lisbon, Portugal, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁶Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁷Rheumatology, Instituto Português de Reumatologia, Lisbon, Portugal, ⁸Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE, Lisbon, Portugal, ⁹Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal, ¹⁰Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Lisboa, Portugal, ¹¹Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ¹²Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands, ¹³Department of Rheumatology, Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: A BASDAI ≥4 has often been required to start TNF inhibitors (TNFi) therapy in patients with axial SpA (axSpA). However, this cut-off of high…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].